Innokin Trine: A Revolutionary Rechargeable E-Cigarette with Replaceable Battery

Oct.12.2024
Innokin Trine: A Revolutionary Rechargeable E-Cigarette with Replaceable Battery
A new Innokin Trine e-cigarette with replaceable battery has hit shelves in Europe, meeting upcoming EU regulations.

Recently, 2Firsts noticed a new type of replaceable battery e-cigarette called the Innokin Trine being showcased at a tobacco exhibition in Dortmund. The product, launched by e-cigarette brand Innokin, is now available on e-cigarette retail websites in regions such as the UK and Germany. With its design allowing for replaceable batteries, the product complies with the new regulations set to be implemented by the EU Battery Directive in 2026.

Innokin Trine: A Revolutionary Rechargeable E-Cigarette with Replaceable Battery
Innokin Trine displayed at the tobacco exhibition in Dortmund by Innokin|Image source: 2Firsts


At the recent Dortmund tobacco exhibition, several exhibitors showcased e-cigarette products with replaceable batteries, including disposable, pod-based, and open-system devices, in response to the EU's Battery Directive. According to the directive, by 2026, batteries in portable devices (such as disposable e-cigarettes) must be easily removable and replaceable by the user.

Innokin Trine: A Revolutionary Rechargeable E-Cigarette with Replaceable Battery
Image Source | Innokin Official Website


The newly released Innokin Trine, an open system product from Innokin, complies with the upcoming new regulations in the European Union market.

Innokin Trine: A Revolutionary Rechargeable E-Cigarette with Replaceable Battery
Image source | Innokin official website


In addition, the main feature of Trine is its "three-in-one" structure: atomizer, detachable and rechargeable battery, control panel. At the same time, the detachable and rechargeable battery enhances the convenience and durability of the device.

Innokin Trine: A Revolutionary Rechargeable E-Cigarette with Replaceable Battery
Image source | Innokin brand official website


Specifically, the main product features of the Innokin Trine include:


E-liquid capacity: 2ml Nicotine concentration: Supports a variety of nicotine levels in e-liquid Battery capacity: 1000mAh removable battery Charging method: Supports Type-C fast charging.


Trine Power Hub charger charges


Backup batteries can also be purchased separately.


Power Mode: Provides a power output of 6-25W.


Function: - Suction activation


Support mouth to lung (MTL) or limit direct lung (RDL) inhale mode.


Compatible with a variety of e-liquid flavors.


Charging indicator light


The screen displays operational parameters such as output power and battery level.


Currently, the Innokin Trine has been listed on the official website of the Innokin e-cigarette brand and major distributor websites in Europe, with a selling price of approximately 19.95 euros.


In addition to the Innokin brand, other brands such as GOLISI and NEXIONE have also introduced similar products with replaceable batteries. 2Firsts will continue to monitor the latest products and market trends in replaceable battery e-cigarette products, providing the public with accurate and authoritative industry information.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | BAT Expands VELO Peach Ice Medium to FamilyMart Stores Nationwide in Japan
Product | BAT Expands VELO Peach Ice Medium to FamilyMart Stores Nationwide in Japan
British American Tobacco Japan (BAT Japan) expanded VELO Peach Ice Medium to FamilyMart stores nationwide in Japan from September 7, 2026. The oral tobacco product first launched on July 6 and had previously been sold through VELO's official online store, glo Store Ginza and tobacco retailers. It combines peach flavor with menthol cooling at a Medium strength level and is priced at JPY 360. Japanese tobacco retailers list 15 pouches per pack. The move adds the new SKU to an existing nationwide FamilyMart distribution network for VELO rather than marking the brand's first entry into the convenience-store chain.
Sep.15
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
German Tobacco Tax Revenue Falls 10.8% Through August as Tax-Paid Cigarette Volume Drops 12.6%
Germany collected €9.789 billion in total tobacco tax revenue from January through August 2026, down 10.8% from a year earlier, according to the Federal Ministry of Finance. Germany's tobacco tax base covers not only cigarettes and fine-cut tobacco but also heated tobacco and vaping liquids taxed as tobacco substitutes. The German Association of the Tobacco Industry and Novel Products, or BVTE, citing federal statistical data, said tax-paid cigarette volume fell 12.6% to 40.6 billion sticks. BVTE is using the latest figures to argue against further tax increases planned from 2027 through 2030, while Germany's parliament is scheduled to hold a first reading of the bill on September 24.
Sep.23
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech launched IKE 2.0 on September 28, initially targeting nicotine products with a platform that combines user identity verification, product authentication, configurable policy controls and data analytics. Products can be authenticated through direct device integration or NFC smart tags. IKE Tech was formed with participation from Ispire's Aspire North America, Berify and Chemular, with Ispire currently holding a 40% interest. Its age-verification component PMTA was accepted by the FDA in 2025 and remains under review. The company did not disclose customer names, commercial deployment volumes, pricing or revenue tied to IKE 2.0.
News
Sep.29 by 2Firsts Perspectives
Italian Financial Police Seize 4.3 Million E-Cigarettes and Smoking Accessories; 28 Reported to Judicial Authorities Across Operations
Italian Financial Police Seize 4.3 Million E-Cigarettes and Smoking Accessories; 28 Reported to Judicial Authorities Across Operations
Italy's Guardia di Finanza announced on October 28 that officers in Latina province had seized approximately 4.3 million e-cigarettes and smoking accessories at an unauthorized warehouse in an operation involving restrictions on the possession and sale of tobacco-related products. Another 300,000 suspected counterfeit or unsafe items were confiscated during separate inspections, bringing total seizures across the operations to more than 4.6 million products. Twenty-eight people were reported to judicial authorities over suspected smuggling and counterfeiting offenses. Officials did not disclose separate vape quantities, the value of the merchandise or alleged violations associated with individual brands.
Enforcement
Oct.29
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands has agreed to acquire 100% of Swedish modern oral nicotine company Yoik Group AB for an initial SEK515 million, equivalent to about US$53.9 million, plus a deferred payment linked to performance over the next two years. Yoik owns nicotine pouch brand Helwit, which held about 3.4% of Sweden’s modern oral nicotine market over the past 12 months. Imperial says the acquisition will more than double its existing share of the Swedish market. Helwit is also sold elsewhere in the Nordics, through European online channels and in selected UK retail outlets.
Sep.08
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22